Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

BACKGROUND: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney disease, including those with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Circulation
Κύριοι συγγραφείς: Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei, Rosenthal, Norm, Jardine, Meg J., Bakris, George, Perkovic, Vlado
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Lippincott Williams & Wilkins 2018
Θέματα:
Original Research Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181277/
https://ncbi.nlm.nih.gov/pubmed/29941478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια